Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
May 8, 2006
- Sanofi-aventis Aims to
May 8, 2006
- Dr A. Endo Awarded Japan Prize for Discovery of Statins
May 8, 2006
- MEDICAL DEVICE NEWS IN BRIEF
April 24, 2006
- Dr Aoki Likely to Be Reappointed President of JPMA
April 24, 2006
- NEW PRODUCTS
April 24, 2006
- Huma to Expand Clinical Trial Volunteer Recruitment Business
April 24, 2006
- Is Pre-screening of Medical Charts by CRCs Illegal?
April 24, 2006
- R&D NEWS IN BRIEF
April 24, 2006
- JPA to Build Database for Comparing Original, GE Drugs
April 24, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 24, 2006
- Rash of Inquiries in Response to Ads for Generics: Taiyo Pharm.
April 24, 2006
- Acquisition of Schering Would Strengthen Specialty Care: Bayer HealthCare
April 24, 2006
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 24, 2006
- Chugai, Takeda, Eisai Hire Most New Graduates
April 24, 2006
- SURVEY 3 articles
April 24, 2006
- BUSINESS NEWS IN BRIEF
April 24, 2006
- Industry Calls For Exemption from Supply of Original Drugs in Full Range of Strengths
April 24, 2006
- REGULATORY NEWS IN BRIEF
April 24, 2006
- Aiming at Sales of \30 Bil. in 2010: Smith & Nephew
April 24, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…